Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.26 USD | -2.41% | -8.04% | -41.49% |
Sales 2024 * | 216M 17.28B | Sales 2025 * | 302M 24.2B | Capitalization | 400M 32.07B |
---|---|---|---|---|---|
Net income 2024 * | -238M -19.06B | Net income 2025 * | -164M -13.14B | EV / Sales 2024 * | 2.4 x |
Net Debt 2024 * | 118M 9.46B | Net Debt 2025 * | 69.33M 5.55B | EV / Sales 2025 * | 1.55 x |
P/E ratio 2024 * |
-1.75
x | P/E ratio 2025 * |
-2.8
x | Employees | 380 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 98.81% |
Latest transcript on Travere Therapeutics, Inc.
1 day | -2.41% | ||
1 week | -8.04% | ||
Current month | -31.78% | ||
1 month | -31.42% | ||
3 months | -38.84% | ||
6 months | -22.65% | ||
Current year | -41.49% |
Managers | Title | Age | Since |
---|---|---|---|
Eric Dube
CEO | Chief Executive Officer | 51 | 03/01/19 |
Chris Cline
DFI | Director of Finance/CFO | 40 | 31/07/14 |
Jula Inrig
CTO | Chief Tech/Sci/R&D Officer | 49 | 03/01/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Tim Coughlin
BRD | Director/Board Member | 57 | 30/03/15 |
Jeffrey Meckler
BRD | Director/Board Member | 57 | 07/10/14 |
Suzanne Bruhn
BRD | Director/Board Member | 60 | 07/04/20 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.15% | 0 M€ | 0.00% | - | |
0.12% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/04/24 | 5.26 | -2.41% | 1,220,072 |
25/04/24 | 5.39 | -1.10% | 1,485,491 |
24/04/24 | 5.45 | -5.05% | 2,777,757 |
23/04/24 | 5.74 | -1.88% | 1,764,302 |
22/04/24 | 5.85 | +2.27% | 1,098,084 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-41.49% | 400M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- TVTX Stock